CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
LeukemiaJul 3, 2026 (epub)
Mingming Zhang, Lianxuan Liu, Shan Fu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated CD7-targeted CAR-T cell therapy in 14 patients with relapsed or refractory CD7-positive acute myeloid leukemia (AML). The study found an objective response rate of 92.3% and a minimal residual disease (MRD)-negative rate of 84.6%. Despite some relapses, the therapy demonstrated a manageable safety profile.
Key findings
- Objective response rate was 92.3%, with an MRD-negative rate of 84.6%.
- Cytokine release syndrome occurred in 92.9% of patients.
- Grade 3-4 cytopenia was observed in 100% of patients.
- 3-year overall survival rate was 34.3%.
Why it matters
The study highlights the potential of CD7 CAR-T cell therapy as a promising treatment option for patients with relapsed or refractory CD7-positive AML, indicating a need for further research to confirm these findings.